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Immunotherapy is now considered the 4th pillar  in  cancer  treatment.  Harnessing the immune system
with immune checkpoint inhibitors, co-stimulatory agonists, vaccines, TLR inhibitors, chimeric antigen
receptor (CAR) T cell has shown clinical benefit in various cancer types. In addition, the combination
of immunotherapy agents and radiotherapy (IMRT or proton beam SBRT) or the so- called metronomic
chemotherapy is under investigation.
Immunotherapy has an established role in the metastatic/recurrent head & neck cancer (HNSCC)
setting. In this context, Burtness presented at ESMO 2018 the KEYNOTE 048 results comparing
standard treatment platinum-based chemotherapy (5-FU with platin) and cetuximab (the control group)
vs pembrolizumab vs combination of pembrolizumab (anti-PD1) with platinum based chemotherapy in
a phase III 1:1:1 randomised trial. The OS was superior in the pembrolizumab arm especially in tumours
expressing PDL-1 (combined positive score >20) (14.9 months vs 10.7 months HR=0.61 p=0.0006).
Also, toxicity was more acceptable in the pembrolizumab group (1).
Based on both preclinical and other solid tumour studies and the fact that several immunological
perturbations are noted in HNSCC, several groups rekindled their interest in neoadjuvant
immunotherapy in locally advanced, resectable tumours. To date, surgery followed by chemo-
radiotherapy is the mainstay treatment in locally advanced disease in most instances.
At ASCO 2017, Uppaluri et al. presented their preliminary data in a phase II trial involving 21 patients
with stage III/IV, HPV-ve, resectable HNSCC with neoadjuvant and post-op pembrolizumab querying
safety and reduction 1-y locoregional recurrence/distast metastases. The results showed that 43% of
patients had pathological response to a single dose of anti-PD1 and 48% had clinical to pathological
downstaging. Equally important, there was no delay in surgery treatment (NCT0229668) (2). More
recently, Duhen et al. checked in a phase Ib trial, the safety and activation of immune response of 16
HNSCC patients who had neoadjuvant anti-OX-40 (co-stimulatory agonist) infusion at 2 days, 1 week
and 2 weeks before surgery.  The treatment was well tolerated and Activation and proliferation of CD4+
and CD8+ memory T-cell populations in both the TME and periphery peaked between 12 and 19 days
after  OX40  infusion,  as  demonstrated  by  increased  levels  of  Ki67,  CD38  and  ICOS.  In  the  TIL,
expression of CD39, ICOS and PD-1 was increased on CD4+ T cells in most patients and the frequency
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of tumour-reactive CD39+CD103+ CD8+ T cells was increased in some patients. IHC analysis revealed
striking changes in tissue integrity and increased lymphocyte infiltrates in 4/16 patients
(NCT02274155) (3). Hitherto, 9 studies involving neoadjuvant immunotherapy are completed or are
underway in HNSCC (Clinicaltrials.gov accessed 2/11/2018).
Seemingly, induction chemotherapy is the prototype, as it has a role in organ preserving chemo-
radiotherapy, but failed to show any substantial efficacy in oral cancer. Nevertheless, neoadjuvant
immunotherapy doesn’t  have direct  cytotoxic effect;  instead,  it  primes T cells  in  the draining lymph
nodes and the primary tumour site in order to recognise tumour noeantigens and kill tumour cells.
Theoretically, there is abundance of neoantigens and TIL can recirculate so they can prevent recurrence,
fully purge any residual disease, and prevent distant metastasis especially in HPV+ OPC In the case of
adjuvant chemo-radiotherapy there may benefit of the abscopal effects (2,4).
Using immunotherapy post biopsy, but prior to definitive surgery, offers a window phase of treatment
in which to deliver therapy and assess clinicoradiologic and biologic response. Various analysis
methods allow for correlative studies aimed at deciphering the temporo-spatial changes in tumor
microenvironment. Whole exome and RNA sequencing platforms can be applied to understand genomic
determinants of immune cell function, facilitating neoantigen prediction modeling and protein
expression analysis. Additionally, T cell receptor clonotyping can determine unique gene rearrangement
sequences that arise in response to antigen presentation in the lymphocytes infiltrating an individual
tumor, and extra- or intracellular cytokine levels can be quantified to understand immune cell signalling
(2).
Despite the aforementioned advantages, there are potential risks pertained to immunotherapy before
surgery.  There is  a  risk of  delaying the surgery due to potential  immune related sides effects,  but  in
some phase I trials this does not seem to be the case as mentioned above. Also, alteration of the immune
profile may alter healing process and delay radiotherapy. The detrimental potential of hyperprogression
should also be considered, as it was described by a French group in 27% patients treated with immune
check point inhibitors (especially in the irradiated field) (2).
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The timing of immunotherapy in order to maximise the T cell activity as well as the role and extend of
lymphadenectomy in the final outcome has yet to be concluded (4).
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